The study failed to show a statistically significant reduction in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale compared to a placebo, according to a Jan. 2 news release from the company.
The key secondary endpoint, a reduction in anhedonia measured by the Snaith-Hamilton Pleasure Scale, also did not achieve statistical significance. However, navacaprant showed an efficiency signal in female participants with a trend toward improvement in both depressive symptoms and anhedonia though the data were not conclusive.
The drug was generally well-tolerated, with a safety profile comparable to placebo. No adverse events were reported and there were no signals of increased suicidal ideation or behavior.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.